Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, December 29, 2015
Mylan has announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox® Tablets.
read more
Mylan has announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® Tablets.
read more
Mylan has announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules.
read more
Friday, November 20, 2015
Mylan has announced the U.S. launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity amphetamine product), 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and...
read more
Mylan announced the U.S. launch of Tadalafil Tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and Company's Adcirca.
read more
Friday, September 21, 2018
Mylan announced the U.S. launch of Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda's Ampyra.
read more
Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility.
read more
Generic drugmaker Mylan announced layoffs of about 15 percent of its workforce at their manufacturing plant in Morgantown, West Virginia.
read more
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation to patents for Herceptin® (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
read more
Wednesday, October 17, 2018
MWI Animal Health announced the acquisition of ALLYDVM, a technology company that provides veterinary practices with a range of cloud-based software services.
read more
Tuesday, December 01, 2020
Mustang Bio and Minaris have signed an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of XSCID in Europe.
read more
Thursday, October 08, 2020
Mustang Bio has acquired rights to SIRION’s LentiBOOST technology for the development of MB-207.
read more
Tuesday, September 03, 2019
BioLife Solutions announced Mustang Bio has adopted BioLife's CryoStor cell freeze media and evo cold chain system for use in current and upcoming clinical trials.
read more
Thursday, November 13, 2025
Mursla Bio announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
read more
Monday, November 14, 2022
Mural Health Technologies announced the launch of its new platform, Mural Link, built to make it easy to participate in global clinical research studies.
read more